Last-Hope cancer drug offered to desperate patients
NCT ID NCT04566393
Summary
This program provides access to an investigational drug called ulixertinib for patients with advanced cancers that have specific genetic changes (MAPK pathway mutations). It is for people who have run out of other treatment options. The drug aims to control the cancer's growth, either alone or combined with other tolerable treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health System/Overlook Medical Center
AVAILABLESummit, New Jersey, 07901, United States
Contact
-
Cancer Partners of Nebraska
AVAILABLELincoln, Nebraska, 68510, United States
Contact
-
Clearview Cancer Institute
AVAILABLEHuntsville, Alabama, 35805, United States
Contact
-
Hirschfeld Oncology
AVAILABLEBrooklyn, New York, 11206, United States
Contact
-
Hoag Memorial Hospital Presbyterian
AVAILABLENewport Beach, California, 92663, United States
Contact
-
Hunterdon Hematology Oncology
AVAILABLEFlemington, New Jersey, 08822, United States
Contact
-
Infirmary Cancer Care
AVAILABLEMobile, Alabama, 36604, United States
Contact
-
Lake Region Healthcare
AVAILABLEFergus Falls, Minnesota, 56537, United States
Contact
-
Lehigh Valley Health Network
AVAILABLEAllentown, Pennsylvania, 18103, United States
Contact
-
MD Anderson
AVAILABLEHouston, Texas, 77030, United States
Contact
-
Mary Bird Perkins Cancer Center
AVAILABLEBaton Rouge, Louisiana, 70809, United States
Contact
-
MedStar Georgetown University Hospital
AVAILABLEWashington D.C., District of Columbia, 20007, United States
Contact
-
Mercy Medical Center
AVAILABLECedar Rapids, Iowa, 52403, United States
Contact
-
Monmouth Medical Center
AVAILABLELong Branch, New Jersey, 07740, United States
Contact
-
Nebraska Hematology Oncology
AVAILABLELincoln, Nebraska, 68506, United States
Contact
-
Oakland Macomb Cancer Specialists
AVAILABLESterling Heights, Michigan, 48314, United States
Contact
-
Orlando Health
AVAILABLEOrlando, Florida, 32806, United States
Contact
-
Our Lady of the Lake Hospital
AVAILABLEBaton Rouge, Louisiana, 70808, United States
Contact
-
PCR Oncology
AVAILABLEArroyo Grande, California, 93420, United States
Contact
-
Providence Saint John's Health Center
AVAILABLESanta Monica, California, 90404, United States
Contact
-
Stony Brook Cancer Center
AVAILABLEStony Brook, New York, 11794, United States
Contact
-
The Christ Hospital
AVAILABLECincinnati, Ohio, 45219, United States
Contact
-
The Minniti Center for Medical Oncology and Hematology
AVAILABLEMickleton, New Jersey, 08056, United States
Contact
-
UTHealth - Tyler
AVAILABLETyler, Texas, 75701, United States
Contact
-
UTHealth Houston
AVAILABLEHouston, Texas, 77030, United States
Contact
-
Unity Point Health - St. Lukes Hospital
AVAILABLECedar Rapids, Iowa, 52403, United States
Contact
-
xCures Inc.
AVAILABLESan Francisco, California, 94105, United States
Conditions
Explore the condition pages connected to this study.